SCHEMBL25822289

SCHEMBL25822289

Fc1cc(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)ccc1N1CCC2(CC1)OCCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.39
ALDH1A1 P00352 5/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
KDM4E B2RXH2 3/20 0.35
HPGD P15428 3/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
MAPK1 P28482 3/20 0.35
GAA P10253 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RCE1 Q9Y256 1/20 0.35
HCRTR1 O43613 2/20 0.35
TSHR P16473 2/20 0.35
HSD17B10 Q99714 2/20 0.35
POLB P06746 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30475477 1.00 GRM5 (0.39) GRM5ALDH1A1SMN1; SMN2FFAR4KDM4E
SCHEMBL25819188 0.90 FFAR4 (0.39) GRM5ALDH1A1SMN1; SMN2FFAR4KDM4E
SCHEMBL24880555 0.88 GRM5 (0.38) GRM5ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL30112351 0.88 GRM5 (0.38) GRM5ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL31251917 0.86 GRM5 (0.38) GRM5ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL30484054 0.85 GRM5 (0.40) GRM5ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL25831440 0.85 GRM5 (0.40) GRM5ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL29013184 0.85 GRM5 (0.38) GRM5FFAR4LMNAPDE3BPDE3A
SCHEMBL25938824 0.84 GRM5 (0.40) GRM5ALDH1A1SMN1; SMN2FFAR4MAPT
SCHEMBL24753633 0.84 HTR1A (0.46) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 GRM5 3397/4885ALDH1A1 4008/4885SMN1; SMN2 3089/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 GRM5 1390/4885ALDH1A1 2752/4885SMN1; SMN2 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.